title: Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues.
abstract: The relationship between exogenous contraceptive hormones and permissiveness of the female genital tract to human immunodeficiency virus type 1 (HIV-1) is the subject of renewed debate. To better characterize the effect of depot medroxyprogesterone acetate (DMPA) on HIV-1 cellular targets and epithelial integrity in the vagina, we compared leukocyte populations, markers of activation and proliferation, and the density of intercellular junctional proteins in the vaginal epithelium of women during the follicular and luteal phases of the menstrual cycle and approximately 12 weeks after receiving a DMPA injection. This prospective cohort study involved 15 healthy women. Vaginal biopsies were obtained in the follicular and luteal phases of the menstrual cycle, and approximately 12 weeks following a 150-mg intramuscular injection of DMPA. Leukocyte populations, activation phenotype, and epithelial tight junction and adherens proteins were evaluated by immunohistochemistry. After receiving DMPA, the numbers of CD45, CD3, CD8, CD68, HLA-DR, and CCR5 bearing immune cells were significantly (p<0.05) increased in vaginal tissues, compared to the follicular and/or luteal phases of untreated cycles. There were no significant differences in immune cell populations between the follicular and luteal phases of the control cycle. There were also no statistically significant differences in epithelial thickness and density of epithelial tight junction and adherens proteins among the follicular, luteal, and post-DMPA treatment sampling points. In this pilot study, vaginal immune cell populations were significantly altered by exogenous progesterone, resulting in increased numbers of T cells, macrophages, and HLA-DR- and CCR5-positive cells.
authors.affiliation: CONRAD, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA.
authors.forename: Neelima
authors.initials: N
authors.lastname: Chandra
authors.forename: Andrea Ries
authors.initials: AR
authors.lastname: Thurman
authors.forename: Sharon
authors.initials: S
authors.lastname: Anderson
authors.forename: Tina Duong
authors.initials: TD
authors.lastname: Cunningham
authors.forename: Nazita
authors.initials: N
authors.lastname: Yousefieh
authors.forename: Christine
authors.initials: C
authors.lastname: Mauck
authors.forename: Gustavo F
authors.initials: GF
authors.lastname: Doncel
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D001706:Biopsy; D002452:Cell Count; D015331:Cohort Studies; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D003692:Delayed-Action Preparations / Q000008:administration & dosage*; D005260:Female; D015497:HIV-1; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D007962:Leukocytes / Q000737:chemistry / Q000276:immunology*; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D009092:Mucous Membrane / Q000166:cytology* / Q000276:immunology; D011446:Prospective Studies; D019713:Receptors, CCR5 / Q000032:analysis; D014621:Vagina / Q000166:cytology* / Q000276:immunology
chemical_list: D015703:Antigens, CD; D003271:Contraceptive Agents, Female; D003692:Delayed-Action Preparations; D006684:HLA-DR Antigens; D019713:Receptors, CCR5; D017258:Medroxyprogesterone Acetate